Investigational COVID-19 Vaccine Well-Tolerated and Generates Immune Response in Older Adults | NIH: National Institute of Allergy and Infectious Diseases

Investigational COVID-19 Vaccine Well-Tolerated and Generates Immune Response in Older Adults | NIH: National Institute of Allergy and Infectious Diseases

Tuesday, September 29, 2020 Investigational COVID-19 Vaccine Well-Tolerated and Generates Immune Response in Older Adults A paper published today in the New England Journal of Medicine describes some of the findings from a Phase 1 trial of an investigational mRNA vaccine. The study, which was supported by NIAID, began in March and was expanded to enroll older adults about one month later. The mRNA-1273 vaccine appears to be well-tolerated and generates a strong immune response in older adults. In general, older adults are more vulnerable to complications of COVID-19, and understanding how the vaccine affects older adults is a critical part of testing its safety and efficacy.